Compare UNB & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | GLSI |
|---|---|---|
| Founded | 1891 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 123.9M |
| IPO Year | 1998 | 2020 |
| Metric | UNB | GLSI |
|---|---|---|
| Price | $24.70 | $28.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 10.4K | ★ 1.0M |
| Earning Date | 01-21-2026 | 11-14-2025 |
| Dividend Yield | ★ 5.85% | N/A |
| EPS Growth | ★ 27.30 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $52,533,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.96 | ★ N/A |
| Revenue Growth | ★ 13.25 | N/A |
| 52 Week Low | $20.65 | $7.78 |
| 52 Week High | $36.00 | $34.10 |
| Indicator | UNB | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 60.32 |
| Support Level | $23.95 | $20.00 |
| Resistance Level | $24.84 | $34.10 |
| Average True Range (ATR) | 0.55 | 4.58 |
| MACD | -0.02 | 0.12 |
| Stochastic Oscillator | 59.78 | 62.91 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.